EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Difluoromethylornithine modulates mutant K-RAS signaling pathways in pancreatic cancer cells

Hwudaurw Chen, David E Stringer, Haiyan Cui, Eugene W Gerner, Natalia A Ignatenko iD

Amino Acids · 2026

DOI: 10.1007/s00726-026-03559-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Amino Acids, 2026. Verfasst von Hwudaurw Chen und 4 weiteren Autor:innen. Beteiligte Einrichtung: University of Arizona Cancer Center, Tucson, AZ, USA. Hauptthemen laut MEDLINE: Eflornithine, Pancreatic Neoplasms, Signal Transduction, Proto-Oncogene Proteins p21(ras). Die Arbeit nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oncogenic mutations in the K-RAS small GTPase occur in more than 90% of human PDACs and cause dysregulation of multiple metabolic pathways, including polyamine metabolism. The goal of this study was to determine whether blocking polyamine synthesis with the irreversible inhibitor α-difluoromethylornithine (DFMO) provides a valid approach to targeting metabolic dependency in mutant K-RAS pancreatic tumors, compared with direct suppression of the oncogenic K-RAS protein. The anti-tumor activity of DFMO was evaluated in vitro and in vivo in the MIA PaCa-2 pancreatic cell line ( K-RAS G12C ) and its isogenic clonally selected line M-27, which does not express a functional GTP-bound RAS protein. MIA PaCa-2 and M-27 cells had comparable intracellular polyamine levels, and DFMO treatment effectively suppressed total polyamine levels in both cell lines ( p < 0.01). DFMO reduced the protein levels of phosphorylated extracellular signal-regulated kinases 1 and 2 (ERK1/2) and RAS-like small GTPase A (RalA) but induced the phosphoinositide 3-phosphate kinase (PI3K) signaling pathway. Additionally, the intracellular levels of K-RAS and hypusinated eukaryotic initiation factor 5 A (eIF5A Hyp ) proteins were suppressed in DFMO-treated MIA PaCa-2 cells. DFMO therapy regimen (500 mg/kg/day by oral gavage) significantly improved survival rates of SCID mice with orthotopically implanted MIA PaCa-2 cell line (MIA PaCa-2 control vs. MIA PaCa-2 DFMO, p = 0.0184), with median survival time comparable to animals implanted with M-27 cell line (MIA PaCa-2 control vs. M-27 control, p = 0.0204). DFMO treatment did not significantly improve survival of mice bearing M-27 tumors (M-27 control vs. M-27 DFMO, p = 0.6055). These data indicate that DFMO treatment suppresses pancreatic tumorigenesis driven by the mutant K-RAS oncogene similarly to the targeted elimination of the active GTP-bound RAS protein.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EflornithinePancreatic NeoplasmsSignal TransductionProto-Oncogene Proteins p21(ras)Antineoplastic AgentsHumansAnimalsCell Line, TumorMiceMutationXenograft Model Antitumor Assaysras ProteinsPolyamines

Stichwörter der Autor:innen

DifluoromethylornithineHypusinated eIF5APancreatic adenocarcinomaPancreatic orthotopic mouse modelPolyaminesRAS-like small GTPase A

Substanzen

EflornithineProto-Oncogene Proteins p21(ras)Antineoplastic Agentsras ProteinsPolyaminesKRAS protein, human

Autor:innen und Institutionen

  • University of Arizona Cancer Center, Tucson, AZ, USA.
  • Department of Cellular & Molecular Medicine, University of Arizona, Tucson, AZ, USA.
  • University of Arizona Cancer Center, Tucson, AZ, USA. nai@arizona.edu.
  • Department of Cellular & Molecular Medicine, University of Arizona, Tucson, AZ, USA. nai@arizona.edu.

ORCID-Profile: Natalia A Ignatenko

Förderung

  • NCI NIH HHS
  • National Cancer Institute

Zitieren

APA

Chen, H., Stringer, D. E., Cui, H., Gerner, E. W., & Ignatenko, N. A. (2026). Difluoromethylornithine modulates mutant K-RAS signaling pathways in pancreatic cancer cells. Amino Acids. https://doi.org/10.1007/s00726-026-03559-5

Vancouver

Chen H, Stringer DE, Cui H, Gerner EW, Ignatenko NA. Difluoromethylornithine modulates mutant K-RAS signaling pathways in pancreatic cancer cells. Amino Acids. 2026. doi:10.1007/s00726-026-03559-5

BibTeX
@article{Chen2026,
  author = {Chen, Hwudaurw and Stringer, David E and Cui, Haiyan and Gerner, Eugene W and Ignatenko, Natalia A},
  title = {Difluoromethylornithine modulates mutant K-RAS signaling pathways in pancreatic cancer cells},
  journal = {Amino Acids},
  year = {2026},
  doi = {10.1007/s00726-026-03559-5}
}
Kostenlos starten →